AR
GLUE icon

Advisory Research’s Monte Rosa Therapeutics GLUE Stock Holding History

Advisory Research’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$760K Buy
31,396
+160
+0.5% +$3.02K 0.08% 121
2026
Q1 		$514K Sell
31,236
-31,984
-51% -$612K 0.06% 128
2025
Q4 		$991K Buy
+63,220
New +$852K 0.12% 108

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Advisory Research's GLUE Position: Q2 2026 in Review

Advisory Research increased its Monte Rosa Therapeutics (GLUE) stake by 0.51% in Q2 2026, buying an estimated $3.02K and bringing the position to 31,396 shares worth $760K. The position accounts for 0.08% of the portfolio, ranked #121.

Advisory Research first reported a position in GLUE in Q4 2025 and has held it in 3 quarters since. The position peaked at $991K in Q4 2025. 193 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Advisory Research held 31,396 shares of Monte Rosa Therapeutics worth $760K as of Q2 2026.
  • Advisory Research bought 160 Monte Rosa Therapeutics shares in Q2 2026, an estimated $3.02K.
  • Monte Rosa Therapeutics made up 0.08% of Advisory Research's portfolio in Q2 2026, its #121 holding.
  • Advisory Research first reported a position in Monte Rosa Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Advisory Research's Monte Rosa Therapeutics position peaked at $991K in Q4 2025.
  • 193 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Advisory Research's 13F filing for Q2 2026, filed 13 Aug 2026.